Synthesis, spectroscopic characterizations, enzyme inhibition, molecular docking study and DFT calculations of new Schiff bases of sulfa drugs


Alyar S., Sen T., ÖZDEMİR ÖZMEN Ü. , ALYAR H., ADEM Ş., Sen C.

JOURNAL OF MOLECULAR STRUCTURE, vol.1185, pp.416-424, 2019 (Journal Indexed in SCI) identifier identifier

  • Publication Type: Article / Article
  • Volume: 1185
  • Publication Date: 2019
  • Doi Number: 10.1016/j.molstruc.2019.03.002
  • Title of Journal : JOURNAL OF MOLECULAR STRUCTURE
  • Page Numbers: pp.416-424

Abstract

New Schiff bases were synthesized (Z)-4-((4-(diethylamino) benzylidene) amino)-N-(3,4-dimethylisoxazol-5-yl) benzenesulfonamide (L1) and (Z)-4-((4-(dimethylamino)benzylidene)amino)-N-(5-methylisoxazol-3-yl) benzenesulfonamide (L2) derived from sulfamethoxazole (S1)/sulfisoxazole (S2) and substituted salicylaldehyde. The synthesized compounds were characterized by FT-IR, H-1-C-13 NMR, LC-MS. We evaluated the effects of compounds on eight enzyme activities by spectrophotometric assays at final concentrations of 0.5-5 mu g. L1 acted as an inhibitor on cholesterol esterase, tyrosinase and alpha-amylase activities with IC50 values 38, 38 and 173 mu M. Tyrosinase, alpha-glucosidase, cholesterol esterase, and a-amylase enzymes were inhibited by L2 with IC50 values 24, 46, 63, and 231 mu M. To comprehend the binding interactions between the inhibitors and enzymes with low IC50 values, molecular docking studies of compounds were performed for cholesterol esterase and tyrosinase. Finally, molecular docking was performed to determine the probable binding mode of the designed compounds into the active site of enzymes. DFT calculations were carried out at the B3LYP levels of theory with 6-311G ++ (d, p) basis set for compounds. (C) 2019 Elsevier B.V. All rights reserved.